LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

66.06 -4.62

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

65.73

Max

69.31

Belangrijke statistieken
By Trading Economics
Inkomsten	24M -167M
Verkoop	40M 195M
EPS	-0.84
Winstmarge	-85.626
Werknemers	834
EBITDA	75M -105M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.87% upside

Dividenden
By Dow Jones
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-706M 13B
Vorige openingsprijs	70.68
Vorige sluitingsprijs	66.06

Nieuwssentiment

By Acuity

33%

67%

93 / 346 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

34.71 / 36.9 Steun & Weerstand

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mei 2026, 22:44 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs Fashion Brand to WHP, G-III Apparel -- 2nd Update

14 mei 2026, 22:27 UTC

Acquisities, Fusies, Overnames

LVMH Selling Marc Jacobs Fashion Brand to WHP, G-III Apparel -- Update

14 mei 2026, 22:12 UTC

Winsten

Applied Materials Raises Outlook as Semiconductor Equipment Demand Grows -- 2nd Update

14 mei 2026, 21:52 UTC

Acquisities, Fusies, Overnames

LVMH to Sell Marc Jacobs

15 mei 2026, 00:00 UTC

Winsten

Honda's Never Faced a Crisis Like This -- And a Comeback Won't Be Easy -- WSJ

14 mei 2026, 23:57 UTC

Acquisities, Fusies, Overnames

Kakao: Stake Sales Aim to Secure Funds for Future Investments

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Share Sale to Lower Kakao Investment's Stake in Dunmau to 4.03%

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao: Affiliate Kakao Investment to Sell 2.3M Dunamu Shares on June 15

14 mei 2026, 23:56 UTC

Marktinformatie

Gold Prices Rise on Strong Demand -- Market Talk

14 mei 2026, 23:56 UTC

Acquisities, Fusies, Overnames

Kakao to Sell 6.55% Stake in Crypto Exchange Operator Dunamu to Hana Financial for KRW1.003T

14 mei 2026, 23:50 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise as AI Enthusiasm Continues -- Market Talk

14 mei 2026, 23:47 UTC

Winsten

JSW Steel: Prolonged Supply-Chain Disruptions Due to Middle East Crisis Pose Risk to Growth >500228.BY

14 mei 2026, 23:47 UTC

Winsten

JSW Steel Results Supported by Higher Steel Prices, One-Off Divestment Gains >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Net INR163.7B Vs. Net INR21.39B >500228.BY

14 mei 2026, 23:46 UTC

Winsten

JSW Steel 4Q Rev INR511.8B Vs. INR448.19B >500228.BY

14 mei 2026, 23:28 UTC

Marktinformatie

New Zealand's Economy Faltering Amid Shocks -- Market Talk

14 mei 2026, 23:00 UTC

Marktinformatie

Australia's One Nation Party Leads In The Polls -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Court Decision 'Negative But Balanced' for Coles -- Market Talk

14 mei 2026, 22:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 mei 2026, 22:35 UTC

Marktinformatie

Fed's Warsh Talks Big Game; Will Focus On Credibility First -- Market Talk

14 mei 2026, 22:11 UTC

Acquisities, Fusies, Overnames

LVMH Agrees to Sell Marc Jacobs -- WSJ

14 mei 2026, 22:06 UTC

Marktinformatie

Applied Materials Gets Improved Visibility into Customer Orders -- Market Talk

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage Results Supported by Higher Contributions From Spritis Business >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Net THB7.37B Vs. Net THB6.74B >Y92.SG

14 mei 2026, 22:04 UTC

Winsten

Thai Beverage 2Q Rev THB86.52B Vs. THB85.35B >Y92.SG

14 mei 2026, 22:00 UTC

Winsten

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q EPS 18c >NU

14 mei 2026, 21:55 UTC

Winsten

Nu Holdings 1Q Rev $4.97B >NU

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

58.87% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 109 USD 58.87%

Hoogste 157 USD

Laagste 94 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

34.71 / 36.9Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

93 / 346 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.